Skip to main content

Table 3 Changes in the proportion of lymphocyte subsets before and after treatment in different treatment groups

From: Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study

 

Immunotherapy group

Chemotherapy group

Before

After

P

Before

After

P

CD4+

34.72 ± 9.50

39.34 ± 10.40

 < 0.001

33.95 ± 8.40

23.95 ± 7.50*

 < 0.001

CD8+

33.26 ± 10.9

26.64 ± 10.12

 < 0.001

31.68 ± 9.26

23.16 ± 9.22*

 < 0.001

CD4+/ CD8+

1.36 ± 2.19

1.83 ± 1.25

0.012

1.16 ± 0.47

1.23 ± 0.64*

0.158

NK

20.34 ± 10.45

22.60 ± 10.01

0.002

21.64 ± 10.71

20.06 ± 10.37*

0.052

Tregs

6.51 ± 1.87

7.21 ± 2.39

0.001

6.73 ± 2.54

5.55 ± 2.11*

 < 0.001

B

8.27 ± 4.30

7.43 ± 4.52

0.117

8.00 ± 4.46

6.87 ± 3.02

0.002

  1. Compared with the immunotherapy group, *P < 0.05